PHARMACY

NACDS’ Anderson applauds NYT column praising pharmacists
The National Association of Chain Drug Stores has issued a letter responding positively to a recent New York Times' article highlighting the role of pharmacists in health care.
NACDS promotes 6 staff members to issues-focused roles
The National Association of Chain Drug Stores team members who have been promoted have a combined 40 years of NACDS service and 80 total years of experience in NACDS’ priority issues, the organization said.

Kroger pharmacies, clinics to roll out point-of-care blood testing

The company this week announced that it would be rolling out PTS Diagnostics' CardioCheck Plus analyzers to pharmacies and clinics, which will help identify whether patients are at risk of a heart attack, a stroke or diabetes at the point of care.
Mayne Pharma launches Tolsura

Mayne's launch of Tolsura provides a new treatment to fight life-threatening fungal infections.
NASP weighs in on DIR fee reform in comments to CMS

The National Association of Specialty Pharmacy has submitted its comments to the Centers for Medicare and Medicaid Services in response to the agency’s proposed Medicare Part D rule reform.
Fresenius Kabi introduces leucovorin calcium injection

Fresenius Kabi's leucovorin calcium injection is the only liquid presentation of leucovorin available.
Hikma launches mitomycin for injection

Hikma has introduced mitomycin for injection, a cancer treatment that had a market value of roughly $43 million for the year ended November 2018, according to IQVIA data.
NCPA: Nearly 3,500 pharmacists voice support for DIR proposal

NCPA's efforts to build support for parts of the Center for Medicare and Medicaid Services' drug pricing rule involving DIR fees has drawn wide support among pharmacists and stakeholders.
NACDS provides recommendations for HHS’ Healthy People 2030 initiative

NACDS highlighted the role of pharmacists in its recommendations for the Department of Health and Human Services' Healthy People 2030 initiative.
IQVIA report: Pharma market to top $1.5T by 2023

An average of 54 new active substance launches per year are expected over the next five years, and two-thirds of launches will be specialty products, lifting specialty share of spending to near 50% by 2023 in most developed markets, the report said.